Skip to content

Acupuncture for the management of side effects caused by chemotherapy among I~ III period breast cancer patients: A randomized, controlled, blind, prospective clinical study

Acupuncture for the management of side effects caused by chemotherapy among I~ III period breast cancer patients: A randomized, controlled, blind, prospective clinical study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022860
Enrollment
Unknown
Registered
2019-04-28
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:Normal acupuncture
Group 2:Shallow acupuncture
Group 3:antanacathartic

Sponsors

First Affiliated Hospital of Nanjing Medical University, Jiangsu Privnce Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 to 70 years old; (2) according to the clinical/pathological staging was diagnosed as I~III stage breast cancer; (3) sign informed consent; (4) proposed A/ EC-T 3-week adjuvant/neoadjuvant chemotherapy program; (5) the breast specialist agrees to conduct the study after evaluating the patient.

Exclusion criteria

Exclusion criteria: (1) combined with other tumors; (2) suffering from the diabetes or peripheral neuropathy; (3) suffering from mental, psychological, immune system diseases, serious digestive system diseases and other diseases affecting treatment and evaluation of curative effect; (4) serious coagulation dysfunction; (5) there are serious skin disorders in the acupuncture area; (6) has not received Chinese medicine or acupuncture treatment in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Standard table for grading of nausea and vomiting caused by chemotherapy;

Secondary

MeasureTime frame
Patient-Generated Subjective Global Assessment;National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0;Neuropathic Pain Scale;brief pain inventory;average daily number of hot flashes;

Countries

China

Contacts

Public ContactLu Jing

First Affiliated Hospital of Nanjing Medical University, Jiangsu Privnce Hospital

lujing0728@163.com+86 15062216761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026